PROCEPT BioRobotics (US:PRCT)2025-02-26 03:41BPH Market and Aquablation Therapy - The U S BPH surgical market represents a $20 billion+ opportunity[12,19] - Approximately 40 million men in the U S currently have BPH[15] - Aquablation therapy is uniquely positioned to become the BPH standard of choice for all prostate sizes and shapes[10] - Around 95% of patients have access to Aquablation therapy[11,59] Clinical and Technological Advantages - The HYDROS Robotic System elevates the Aquablation Therapy experience with AI-powered treatment planning and advanced image guidance[31] - Aquablation offers similar symptom relief to TURP across all prostates in both clinical & commercial studies[50] - WATER study showed that 14 out of 17 participating surgeons had no previous experience with Aquablation therapy, highlighting its ease of adoption[57] Financial Performance and Guidance - Worldwide revenue for Q4 2024 reached $68 2 million, a 57% year-over-year increase[88] - New U S systems sold in Q4 2024 increased by 36% year-over-year[88] - International revenue for Q4 2024 was $7 8 million, a 137% year-over-year increase[88] - The company provides revenue guidance for 2025 of $320 million, representing 43% year-over-year growth[92,93]